ofloxacin has been researched along with Plague in 11 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Plague: An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin cures established pneumonic plague when treatment is initiated after the onset of fever in the lethal aerosol-challenged AGM nonhuman primate model, and can be considered for treatment of other forms of plague." | 7.77 | Levofloxacin cures experimental pneumonic plague in African green monkeys. ( Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W, 2011) |
| "Strains of the plague microbe, antigen complete and defective by fraction I and mouse toxin had the same in vitro susceptibility to ofloxacin (MIC 0." | 7.71 | [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen]. ( Ryzhko, IV; Samokhodkina, ED; Shcherbaniuk, AI; Skalyga, EIu; Tsuraeva, RI, 2002) |
| "Levofloxacin cures established pneumonic plague when treatment is initiated after the onset of fever in the lethal aerosol-challenged AGM nonhuman primate model, and can be considered for treatment of other forms of plague." | 3.77 | Levofloxacin cures experimental pneumonic plague in African green monkeys. ( Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W, 2011) |
| " We explored the effects of neutropenia on the outcome of doxycycline and gentamicin therapy." | 3.74 | Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ( Bassett, J; Drusano, GL; Heine, HS; Kinzig-Schippers, M; Louie, A; Miller, L; Sorgel, F; Sullivan, LJ, 2007) |
| "Strains of the plague microbe, antigen complete and defective by fraction I and mouse toxin had the same in vitro susceptibility to ofloxacin (MIC 0." | 3.71 | [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen]. ( Ryzhko, IV; Samokhodkina, ED; Shcherbaniuk, AI; Skalyga, EIu; Tsuraeva, RI, 2002) |
| "In a parallel study with the pneumonic plague mouse model, after 72 h postinfection, the lungs of animals infected with wild-type (WT) Y." | 1.35 | Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. ( Agar, SL; Baze, WB; Chauhan, S; Chopra, AK; Erova, TE; Fadl, AA; Foltz, SM; Klimpel, GR; Motin, VL; Olano, JP; Peterson, JW; Sha, J; Suarez, G; Wang, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryzhko, IV | 3 |
| Tsuraeva, RI | 2 |
| Anisimov, BI | 1 |
| Trishina, AV | 2 |
| Layton, RC | 1 |
| Mega, W | 1 |
| McDonald, JD | 1 |
| Brasel, TL | 1 |
| Barr, EB | 1 |
| Gigliotti, AP | 1 |
| Koster, F | 1 |
| Verkina, LM | 1 |
| Rosenzweig, JA | 3 |
| Brackman, SM | 1 |
| Kirtley, ML | 3 |
| Sha, J | 4 |
| Erova, TE | 4 |
| Yeager, LA | 1 |
| Peterson, JW | 2 |
| Xu, ZQ | 1 |
| Chopra, AK | 4 |
| van Lier, CJ | 2 |
| Fitts, EC | 1 |
| Kozlova, EV | 1 |
| Tiner, BL | 1 |
| Suarez, G | 2 |
| Sierra, JC | 1 |
| Telepnev, MV | 1 |
| Motin, VL | 2 |
| Samokhodkina, ED | 1 |
| Shcherbaniuk, AI | 1 |
| Skalyga, EIu | 1 |
| Louie, A | 2 |
| Deziel, MR | 1 |
| Liu, W | 1 |
| Drusano, GL | 2 |
| Heine, HS | 1 |
| Sorgel, F | 1 |
| Bassett, J | 1 |
| Miller, L | 1 |
| Sullivan, LJ | 1 |
| Kinzig-Schippers, M | 1 |
| Agar, SL | 1 |
| Baze, WB | 1 |
| Olano, JP | 1 |
| Fadl, AA | 1 |
| Wang, S | 1 |
| Foltz, SM | 1 |
| Chauhan, S | 1 |
| Klimpel, GR | 1 |
| Benner, GE | 1 |
| Andrews, GP | 1 |
| Byrne, WR | 1 |
| Strachan, SD | 1 |
| Sample, AK | 1 |
| Heath, DG | 1 |
| Friedlander, AM | 1 |
11 other studies available for ofloxacin and Plague
| Article | Year |
|---|---|
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, D | 2009 |
Levofloxacin cures experimental pneumonic plague in African green monkeys.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Chlorocebus aethiops; Disease Models, Animal; Infusions, | 2011 |
[Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Lethal Dose 50; Levofloxa | 2010 |
Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Female; Ketolides; Levofloxacin; Ofloxacin; Plague; Rats; Yersinia p | 2011 |
A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
Topics: Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Disease Models, Animal; Female; Flow Cytom | 2013 |
Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Topics: Animals; Antibodies, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Proteins; Immune Sera; | 2013 |
[Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen].
Topics: Animals; Anti-Bacterial Agents; Antigens, Bacterial; Disease Models, Animal; Mice; Mutation; Ofloxac | 2002 |
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Ba | 2007 |
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Doxycycline; Female; Gen | 2007 |
Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Topics: Animals; Anti-Bacterial Agents; Cytokines; Disease Models, Animal; Female; Levofloxacin; Lipoprotein | 2008 |
Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Outer Membrane | 1999 |